18 and older, any sex, with Sepsis. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Vasopressor and Ventilator-free Days (VVFD)Primary· Up to Day 30
The primary outcome measure is VVFD in the first 30 days after the start of treatment. The endpoint was recorded to the nearest day. Participants who died are scored zero days, even if there was a period during which the participant was alive and free of vasopressors and mechanical ventilation. Participants who must return to ventilation and/or vasopressors had their counters reset at zero days.
Group
Value
95% CI
Treatment Protocol
25
0 – 29
Control Protocol
26
0 – 28
Mortality at 30 DaysSecondary· Day 30
The number of participants who did not survive until Day 30 is compared between study arms.
Group
Value
95% CI
Treatment Protocol
56
Control Protocol
60
Intensive Care Unit (ICU) MortalitySecondary· Day 30
The number of participants who died while in the ICU is compared between study arms.
Group
Value
95% CI
Treatment Protocol
52
Control Protocol
49
Mortality at 180 DaysSecondary· Day 180
The number of participants who did not survive until Day 180 is compared between study arms.
Group
Value
95% CI
Treatment Protocol
102
Control Protocol
94
Length of ICU StaySecondary· Day 30
The number of days that participants were in the ICU is compared between study arms.
Group
Value
95% CI
Treatment Protocol
6.7
± 7.3
Control Protocol
6.4
± 6.9
Length of Hospital StaySecondary· Day 30
The number of days that participants were in the hospital is compared between study arms.
Group
Value
95% CI
Treatment Protocol
12.6
± 10
Control Protocol
13.5
± 25.7
Digit Span Test ScoreSecondary· Day 180
The Digit Span Test is used to assesses attention. In the Digit Span Test, participants are read a series of numbers and are asked to repeat them back in the same order. The Digit Span test is scored by the number of digits the participant is able to remember in each test. Higher scores indicate greater ability to pay attention and to remember sequences. The average adult can remember about 7 numbers, plus or minus two, without making an error.
Group
Value
95% CI
Treatment Protocol
8.3
± 3.1
Control Protocol
9.5
± 3.8
Number of Participants With Delirium Assessed With the DeliriumTelephone Confusion Assessment Method (CAM)Secondary· Day 180
The Telephone CAM evaluates dementia with 9-items, where additional questions are asked if symptoms are present. Rather than providing a summary score, if participants exhibit signs of a change in mental status which fluctuates and they experience inattention, along with disorganized thinking or altered level of consciousness, delirium is suggested.
Group
Value
95% CI
Treatment Protocol
0
Control Protocol
0
Hayling Test ScoreSecondary· Day 180
Executive function is assessed with the Hayling Test. The Hayling Test includes two parts of 15 items each where participants complete sentences by providing the missing word. The test is scored as the amount of time it takes, in seconds, to recite a correct response and the appropriateness of the response (in Part 2). Scaled scores range from 1 to 10 where 1 = impaired, 6 = average, and 10 = very superior.
Group
Value
95% CI
Treatment Protocol
4.2
± 1.9
Control Protocol
4.2
± 1.8
Controlled Oral Word Association Test (COWAT) ScoreSecondary· Day 180
Language is assessed with the Controlled Oral Word Association Test (COWAT). Participants generate words beginning with selected letters within 60 seconds. Generating a higher number of words indicates greater language skills.
Group
Value
95% CI
Treatment Protocol
40
± 11
Control Protocol
40
± 11
Wechsler Memory Scale III - Delayed Recall Logical Memory ScoreSecondary· Day 180
Memory is assessed with the Logical Memory subtest from the Wechsler Memory Scale III. Participants listened to two short paragraphs and were asked to recall details from each story after 30 minutes. Scores represent the number of correctly remembered details. Total scores range from 0 to 25 with higher scores reflecting better memory.
Group
Value
95% CI
Treatment Protocol
6.9
± 2.8
Control Protocol
8.1
± 3.2
Telephone Interview for Cognitive Status (TICS)Secondary· Day 180
The Telephone Interview for Cognitive Status (TICS) is an 11-item instrument assessing orientation. Correct responses to the items are scored in a variety of ways, depending on how much of the response is correct. Total scores range from 0 to 41 with higher scores indicating increased cognitive orientation.
Group
Value
95% CI
Treatment Protocol
30.6
± 4.9
Control Protocol
31.2
± 5.2
Adverse events — posted to ClinicalTrials.gov
Time frame: Adverse events potentially associated with the study treatment and serious adverse events were monitored from the time of randomization up to Day 30. Mortality was recorded from the time of randomization up to Day 180..
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
The VItamin C, Thiamine And Steroids in Sepsis (VICTAS) Study is a double-blind, placebo-controlled, adaptive randomized clinical trial designed to investigate the efficacy of the combined use of vitamin C, thiamine and corticosteroids versus indistinguishable placebos for patients with sepsis. The objective of this study is to demonstrate the efficacy of combination therapy using vitamin C, thiamine and corticosteroids in reducing mortality and improving organ function in critically ill patients with sepsis.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07476443 — Renoprotective Role of Vitamin C and Coenzyme Q10 in Nephrotoxicity
· Phase 2, PHASE3
· not yet recruiting
NCT07414693 — Effect of Vitamin C on Length of Hospital Stay in Children With Severe Pneumonia
· Phase 4
· recruiting
NCT06971315 — Impact of Vitamin C on Pain Detection and Tolerance Threshold
· NA
· completed
NCT06794255 — Exploratory Study on the Role of Vitamin C in Promoting Health in Middle-Aged and Elderly Adults
· NA
· recruiting
NCT07341308 — Does Vitamin C Increase the Body Heat Generated By The Nervous System?
· NA
· recruiting
Other recruiting trials for Sepsis
Currently open trials in the same condition.
NCT07507877 — Infraclavicular Axillary Vein Collapsibility Index as a Predictor of Fluid Responsiveness
· recruiting
NCT07154615 — Assessing Immune Dysfunction in Sepsis
· recruiting
NCT07419802 — OxiCLEAR (Oxiris Cytokines and Endotoxin Adsorption Rate) Study
· recruiting
NCT07351344 — African Survey on Sepsis Knowledge (ASK)
· recruiting
NCT07448805 — Accuracy and Safety of the Syai Tag System for Continuous Glucose Monitoring in Intensive Internal Care Unit
· NA
· recruiting
Other Emory University trials
Trials by the same sponsor.
NCT06143345 — HIIT in Isolated IFG: A Proof-of-Concept Study
· NA
· withdrawn
NCT07189819 — Innovative Closed-loop Functional Electrical Stimulation Control System for Augmenting Post-stroke Gait
· NA
· not yet recruiting
NCT06451055 — Low-calorie Diet in Isolated Impaired Fasting Glucose
· NA
· not yet recruiting
NCT07405476 — Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative I
· Phase 2
· recruiting
NCT06708351 — Enhancing Cervical Cancer Screening and Treatment in Women Living With HIV in Kenya, the ENHANCE LINKAge Trial
· NA
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Emory University
Last refreshed: 13 April 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03509350.